Azetukalner vs. placebo for major depression
Treatments studied
Part of Mental health clinical trials.
This trial tests an investigational medication called Azetukalner against a placebo to see if it helps reduce symptoms of major depressive disorder. You may qualify if you are currently in a depressive episode that started in adulthood and have not tried or failed only a few antidepressants.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 74 years old
- Your first depressive episode started before age 50
- Your current depressive episode has lasted at least 6 weeks but no more than 2 years
- You are not taking antidepressants (including benzodiazepines) and can stop taking them for 2 weeks (or longer) before the trial starts
- You have not tried and failed 2 or more antidepressants during your current episode
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is for people who already completed a previous trial of azetukalner for major depressive disorder. It tests the long-term safety and effects of continuing the medication.
This study tests a new oral medication called Zelquistinel (taken as a tablet) against a placebo for treating major depressive disorder. Researchers want to see if it can reduce depression symptoms, especially when other antidepressants haven't been tried or haven't worked.
This study tests an investigational drug called BMS-986511 in adults with moderate to severe depression. The goal is to see if it can improve symptoms.
This study tests an experimental oral pill called azetukalner against a placebo to see if it safely reduces symptoms of major depressive disorder. It is for adults who are currently in a depressive episode lasting 6 weeks to 2 years and have not already tried multiple antidepressants that failed.
This Phase 2 trial tests whether an NMDA-targeted treatment can improve symptoms of major depressive disorder (MDD). You may be able to join if your depression diagnosis and symptom score fit, and you meet several safety and study-following requirements.
This trial studies an NMDA-based treatment for people with major depressive disorder who did not respond to at least one antidepressant. It may help by changing brain signaling linked to depression symptoms.
Hear when a new Major Depressive Disorder trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.